 |
About Our Author - Ed Francis Ed Francis is Executive Editor and Senior Life Sciences Strategist for West Monroe Partners’ Life Sciences practice. Ed has more than 20 years of management consulting experience guiding some of the industry’s most prominent multinational organizations through complex business and technological transformation. Most recently, he was a partner and leader for life sciences strategy, analytics and transformation at IBM Global Business Services.
Subscribe to the Newsletter Here |
|
|
As Sanofi presses ahead with the sale of its European generics business, a private equity firm has bowed out, saying the deal is too expensive, the Financial Times reported. Nordic Capital has bowed out of the bidding due to “very hig...
|
|
|
|
|
|
The sources were right: Only one day after numerous media reports stated Sanofi was nearing a deal with Advent International to sell its copycat drug unit Zentiva, the companies acknowledged that they are in exclusive negotiations. And Adve...
|
|
|
|
|
|
This was a month that will likely be remembered as when Takeda and Shire shook hands on a $62 billion deal for the Japanese drugmaker to take over the rare diseases specialist. If the deal goes through — and there are still a few obstacle...
|
|
|
|
|
|
Barclays analysts did a roll call this week, checking in on each of their stocks and adjusting their ratings and price targets. The results? A bump-up for Merck and a ding for Pfizer. Analyst Geoff Meacham and company upgraded Merck to over...
|
|
|
|
|
|
The $62 billion Takeda-Shire deal surprised everyone—and worries some—as Takeda is borrowing an enormous $31 billion to help pay for the purchase. Does it refresh the industry’s understanding of M&A affordability and open up more ...
|
|
|
|
|
|
Want to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing. On Thursday, the big biotech said it had brought on Pfizer veteran Dan Karp as its EVP of corporate developmen...
|
|
|
|
|
|
Healthcare consolidation took another major step Thursday with Cigna’s move to scoop up the last large independent pharmacy benefits manager Express Scripts in a $54 billion deal. And that could spell more pricing resistance ahead for...
|
|
|
|
|
|
Healthcare companies have revved the deals engine back into high gear. Takeda Pharmaceutical’s possible acquisition of Shire, with its market value of $45 billion, would boost the sector’s year-to-date dollar total for deals to well abo...
|
|
|
|
|
|
M&A shouldn’t be this easy. London-listed drugmaker Shire Plc has nudged Japan’s Takeda Pharmaceutical Co. to up its takeover proposal twice to 44 billion pounds. Now U.S. suitor Allergan Plc is in talks, too. This auction may have ...
|
|
|
|
|
|
Japan’s second-largest drugmaker, Astellas Pharma, is set to use its strong cash position to invest 200 billion yen ($1.86 billion) over the next three years to obtain promising new drugs through acquisitions of startups. With patents...
|
|
|
|
|
Advertise with us
We Reach Quarter Million Decision Makers in:
Healthcare | IT | Retail | Industrial
Advertise with us and reach the right audience.
|
